IP Library Granted Patent US 7,390,784
Granted Patent B2
US 7,390,784 · App. 11/011,499 · Granted Jun 24, 2008

Administering bifunctional molecules containing a drug moiety and presenter protein ligand for therapy

Assignee: The Board of Trustees of the Leland Stanford Junior University
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,390,784
App. No.
11/011,499
Granted
Jun 24, 2008
Kind
B2
Abstract

Bifunctional molecules and methods for their use in the production of binary complexes in a host are provided. The bifunctional molecule is a conjugate of a drug moiety and a presenter protein ligand. In the subject methods, an effective amount of the bifunctional molecule is administered to the host. The bifunctional molecule binds to the presenter protein to produce a binary complex that exhibits at least one of improved affinity, specificity or selectivity as compared to the corresponding free drug. The subject methods and compositions find use in a variety of therapeutic applications.

Claims (9)

1. A method for producing a tripartite complex in a host, said method comprising: administering to said host an effective amount of a bifunctional molecule of less than about 5000 daltons consisting of a drug moiety linked to a ligand for a presenter protein endogenous to said host, wherein said drug moiety binds to a drug target and said ligand binds to a presenter protein that is not said drug target;

whereby said tripartite complex is produced by said ligand of the bifunctional molecule binding to said presenter protein and said drug moiety of said bifunctional molecule binding to said drug target, and said drug moiety of said complex exhibits enhanced drug activity as compared to said drug in free form.

2. The method according to claim 1 , wherein said enhanced drug activity comprises at least one of enhanced affinity, specificity or selectivity of said drug moiety for said drug target.

3. The method according to claim 1 , wherein said drug target is a protein.

4. The method according to claim 1 , wherein said presenter protein endogenous to said host is present at least in the region of said target.

5. The method according to claim 1 , wherein said tripartite complex is characterized by the presence of binding interactions between said presenter protein and said drug target.

6. The method according to claim 5 , wherein said tripartite complex is produced intracellularly.

7. The method according to claim 5 , wherein said tripartite complex is produced extracellularly.

8. The method of claim 1 , wherein said drug moiety and said ligand of said bifunctional molecule are joined by a linking group.

Assignments (4)
EXECUTIVE ORDER 9424, CONFIRMATORY LICENSE Recorded Nov 23, 2008
From: STANFORD UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 021878/0918 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 15, 2005
From: HOWARD HUGHES MEDICAL INSTITUTE
To: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Reel/Frame 016400/0862 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 17, 2005
From: BRIESEWITZ, ROGER; CRABTREE, GERALD R.
To: HOWARD HUGHES MEDICAL INSTITUTE
Reel/Frame 016162/0261 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 17, 2005
From: WANDLESS, THOMAS; VOGEL, KURT; RAY, GREGORY
To: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Reel/Frame 016162/0269 →
Continuity (4)
Continuation 1002593600 · Dec 21, 2001
Division 0931693200 · May 21, 1999
Provisional Application 6008645100 · May 22, 1998
Related Publication 20050209146A1 · Sep 22, 2005